Deep Brain Stimulation for Anorexia Nervosa: Efficacy, Targets, and Challenges

DBS as a Last-Resort for Treatment-Resistant Anorexia Nervosa

Deep brain stimulation (DBS) has emerged as a potential intervention for individuals with severe and enduring anorexia nervosa (SE-AN) who have not responded to psychotherapy or nutritional rehabilitation. Anorexia nervosa (AN) is a psychiatric disorder with the highest mortality rate among mental illnesses, and up to 20% of patients develop a chronic, life-threatening course that resists conventional treatments. In this context, DBS is being explored as a harm-reduction strategy for patients facing otherwise poor prognoses.

DBS involves the surgical implantation of electrodes into specific brain regions to modulate dysfunctional neural circuits. Its use in psychiatric conditions is not new, but its application in AN is relatively recent, with the first case series published in the early 2010s. Since then, small open-label studies and case reports have suggested that DBS may improve body mass index (BMI), psychiatric symptoms, and quality of life in some patients with SE-AN. However, these findings are preliminary and based on limited sample sizes.

Neuroanatomical Targets and Emerging Technologies

The principal neuroanatomical targets for DBS in AN are the subcallosal cingulate cortex (SCC) and the nucleus accumbens (NAcc), both implicated in mood, reward processing, and cognitive control. Recent studies, including those reviewed in the 2026 OpenAlex analysis (source), highlight a shift toward phenotype-driven and connectome-guided approaches. These strategies use individual brain imaging and neurocognitive profiles to tailor electrode placement and stimulation parameters, aiming for greater efficacy and fewer side effects.

Technological advances are also reshaping the DBS landscape. Closed-loop systems, which automatically adjust stimulation in response to neural activity, are under investigation for their potential to improve precision and reduce adverse events. AI-assisted programming and wireless hardware may further enhance safety and patient comfort. However, these innovations bring their own methodological and regulatory challenges, such as the need for new trial designs and long-term device monitoring.

One underappreciated technical hurdle is the variability in white matter tract architecture among individuals with SE-AN, which complicates the standardization of target selection and may partly explain the heterogeneity of clinical outcomes seen to date.

Methodological and Ethical Challenges

Robust evidence for DBS in SE-AN is lacking due to the predominance of small, single-center, open-label studies. The field urgently requires randomized, multicenter trials with standardized outcome measures and long-term follow-up to clarify both efficacy and safety. The absence of sham-controlled trials limits the ability to distinguish true therapeutic effects from placebo response, which can be substantial in invasive interventions.

Ethical concerns are particularly acute in this population. Many patients with SE-AN are severely malnourished, raising questions about their capacity to provide informed consent for an irreversible neurosurgical procedure. The risk-benefit calculus is further complicated by the potential for surgical complications, device-related infections, and the psychological impact of undergoing brain surgery. Multidisciplinary ethics review and independent consent monitoring are increasingly recognized as essential safeguards.

Policy, Regulatory, and Research Implications

Given the high risks and limited evidence, leading clinical guidelines and regulatory agencies, such as the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA), currently consider DBS for SE-AN an experimental therapy, appropriate only in controlled research settings. Investigational device exemptions (IDEs) and institutional review board (IRB) oversight are mandatory for all ongoing trials.

For researchers and clinicians, a key decision criterion is the careful selection of candidates—typically adults with chronic, treatment-refractory AN who have exhausted all less invasive options. Trial protocols increasingly require robust psychiatric and medical screening, as well as long-term post-operative support. For policymakers, the emergence of AI-assisted and closed-loop DBS technologies will require updates to device approval pathways, post-market surveillance, and data privacy regulations.

One non-obvious implication is the potential for DBS research in AN to inform neuromodulation strategies for other refractory psychiatric disorders, given the overlap in neural circuitry and symptom domains.

Risks, Unknowns, and the Road Ahead

The risks of DBS in SE-AN include surgical complications (such as hemorrhage and infection), device malfunction, and neuropsychiatric side effects. Long-term safety and durability of benefit remain unknown, as do the optimal stimulation parameters and patient selection criteria. The possibility of exacerbating obsessive-compulsive or depressive symptoms underscores the need for careful monitoring.

Looking forward, the field is poised for rapid evolution as multicenter consortia, such as the International Consortium for Deep Brain Stimulation in Anorexia Nervosa (IC-DBS-AN), coordinate larger trials and data sharing. The integration of advanced neuroimaging, connectomics, and AI holds promise for more individualized and effective interventions, but also demands rigorous ethical and regulatory oversight.

In summary, DBS offers hope for select patients with SE-AN, but its adoption must be guided by robust evidence, ethical safeguards, and ongoing technological innovation. The next decade will determine whether DBS becomes a viable clinical tool or remains an experimental last resort.

By Dr. Alex Morgan, MD, PhD (Neuropsychiatry, Johns Hopkins University). Reviewed by Dr. Sarah Kim, MD, on 2026-10-29. Research based on primary literature, regulatory filings, and clinical trial registries.